September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Assessment of residual effects due to topical medication on corneal stiffness in primary open angle glaucoma
Author Affiliations & Notes
  • Sushma Tejwani
    Glaucoma, Narayana Nethralaya, Bangalore, India
  • Mathew Francis
    Narayana Nethralaya, Bangalore, India
  • Shoruba Dinakaran
    Glaucoma, Narayana Nethralaya, Bangalore, India
  • Rahul Mehta
    Glaucoma, Narayana Nethralaya, Bangalore, India
  • rohit shetty
    Narayana Nethralaya, Bangalore, India
  • Abhijit Sinha Roy
    Narayana Nethralaya, Bangalore, India
  • Footnotes
    Commercial Relationships   Sushma Tejwani, None; Mathew Francis, None; Shoruba Dinakaran, None; Rahul Mehta, None; rohit shetty, Allergan (F), Carl zeiss (F), Narayana Nethralaya (P); Abhijit Sinha Roy, Avedro (F), Bioptigen (F), Carl zeiss (F), Cleveland Clinic Innovations (P), Narayana Nethralaya (P), Topcon (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3547. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sushma Tejwani, Mathew Francis, Shoruba Dinakaran, Rahul Mehta, rohit shetty, Abhijit Sinha Roy; Assessment of residual effects due to topical medication on corneal stiffness in primary open angle glaucoma. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3547.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We studied whether topical medication in primary open angle glaucoma (POAG) eyes altered the corneal stiffness using air-puff applanation and a viscoelastic model.

Methods : A total of 48 POAG eyes (60 ± 10 years) on glaucoma medication and 44 normal eyes (62 ± 10 years) were analyzed using Corvis-ST (OCULUS Optikgerate Gmbh, Germany), an air-puff applanation device using high speed scheimpflug imaging to measure corneal deformation. Patients were grouped into those using prostaglandin only, beta blocker only and a combination of prostaglandin plus beta blocker. In the combination group only one medication from each type was used. A viscoelastic model was applied to corneal deformation (Figure 1), which performed explicit quantification of corneal stiffness (kc), extra-ocular tissue stiffness (kg) and viscosity (µg). These parameters were then analyzed using multivariate analysis of covariance, using intraocular pressure (IOP) and central corneal thickness (CCT) as covariates. A p<0.05 was considered statistically significant. All measurements are reported as mean ± standard error of the mean.

Results : Mean kc was 108.92 ± 2.90 N/m, 120.87 ± 6.28 N/m, 124.24 ± 5.51 N/m and 105.45 ± 4.94 N/m in the normal, prostaglandin group, beta blocker group and combination group, respectively. Multivariate analyses showed that both IOP (p=0.001) and type of medication (p=0.02) significantly correlated with kc indicating higher stiffness in the prostaglandin group and beta blocker group. Eyes in the combination group had kc similar to normal eyes (p>0.05). CCT (p=0.25), kg (p = 0.81) and µg (p = 0.89) were similar between the groups.

Conclusions : The study provided clinical evidence of modulated corneal stiffness in treated POAG eyes. However, the reasons behind differential modulation of corneal stiffness only in eyes using single medication are not fully understood. Further investigation with larger sample size is required.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×